	US 12,454,559 B2
	Activating mitotic checkpoint control mechanisms
Ajit P. Joglekar, Ann Arbor, MI (US); and Pavithra Aravamudhan, Nashville, TN (US)
Assigned to The Regents of the University of Michigan, Ann Arbor, MI (US)
Filed by The Regents of the University of Michigan, Ann Arbor, MI (US)
Filed on Feb. 27, 2023, as Appl. No. 18/175,303.
Application 18/175,303 is a continuation of application No. 16/836,335, filed on Mar. 31, 2020, abandoned.
Application 16/836,335 is a continuation of application No. 15/355,824, filed on Nov. 18, 2016, granted, now 10,669,320, issued on Jun. 2, 2020.
Claims priority of provisional application 62/256,971, filed on Nov. 18, 2015.
Prior Publication US 2024/0043480 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); A61K 38/45 (2006.01); C12N 9/12 (2006.01)

CPC C07K 14/47 (2013.01) [A61K 38/45 (2013.01); C12N 9/12 (2013.01); C12Y 207/12002 (2013.01); C07K 2319/70 (2013.01)]

8 Claims

1. A cellular or in vitro biochemical system comprising:

(a) a polypeptide having at 95% sequence identity to a kinase domain of the wild-type Mps1 (SEQ ID NO:2) linked to a first dimerization element; and

(b) a polypeptide having at 95% sequence identity to a phosphodomain of the wild-type KNL1 (SEQ ID NO:5) linked to a second dimerization element,

wherein the kinase domain is capable of phosphorylating the phosphodomain, and

wherein dimerization of the first dimerization element and second dimerization element facilitates phosphorylation of the KNL1 polypeptide by the Mps1 polypeptide.